EGFR and neoplasm: Groups of mice pre-injected with unlabeled nimotuzumab before the injection of 89Zr-8709-scFv-Fc also showed similar tumor uptake at 24 h and 120 h p.i. (Figure 5b), confirming that a blocking dose of unlabeled nimotuzumab (domain III binder) did not alter the binding of 89Zr-8709-scFv-Fc (domain II binder) to EGFR.